Genmab (GMAB)
(Real Time Quote from BATS)
$30.11 USD
-0.52 (-1.70%)
Updated Mar 28, 2024 10:46 AM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Genmab AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4,085 | 3,161 | 3,077 | 2,463 | 1,645 |
Receivables | 718 | 857 | 541 | 415 | 448 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 4,812 | 4,018 | 3,617 | 2,879 | 2,093 |
Net Property & Equipment | 139 | 113 | 99 | 69 | 36 |
Investments & Advances | 19 | 19 | 59 | 166 | 22 |
Other Non-Current Assets | 9 | 7 | 4 | 3 | 2 |
Deferred Charges | 31 | 36 | 42 | 27 | 21 |
Intangibles | 15 | 21 | 40 | 52 | 70 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5,124 | 4,287 | 3,918 | 3,239 | 2,270 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 8 | 0 | 0 | 0 | 11 |
Other Current Liabilities | 340 | 248 | 240 | 186 | 126 |
Total Current Liabilities | 361 | 258 | 249 | 192 | 141 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 70 | 68 | 77 | 75 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 2 | 2 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 534 | 402 | 387 | 310 | 164 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10 | 9 | 11 | 10 | 10 |
Capital Surplus | 1,809 | 1,743 | 1,914 | 1,822 | 1,762 |
Retained Earnings | 2,762 | 2,119 | 1,594 | 1,089 | 319 |
Other Equity | 9 | 14 | 13 | 8 | 15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4,590 | 3,886 | 3,531 | 2,929 | 2,106 |
Total Liabilities & Shareholder's Equity | 5,124 | 4,287 | 3,918 | 3,239 | 2,270 |
Total Common Equity | 4,590 | 3,886 | 3,531 | 2,929 | 2,106 |
Shares Outstanding | 660.70 | 659.60 | 657.10 | 655.40 | 650.70 |
Book Value Per Share | 6.95 | 5.89 | 5.37 | 4.47 | 3.24 |
Fiscal Year End for Genmab AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4,085 | 4,019 | 3,636 | 3,537 | 3,161 |
Receivables | 718 | 793 | 703 | 531 | 857 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 10 | 7 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 4,812 | 4,822 | 4,346 | 4,068 | 4,018 |
Net Property & Equipment | 139 | 138 | 133 | 123 | 113 |
Investments & Advances | 19 | 23 | 27 | 20 | 19 |
Other Non-Current Assets | 9 | 5 | 5 | 6 | 7 |
Deferred Charges | 31 | 37 | 37 | 36 | 36 |
Intangibles | 15 | 17 | 19 | 19 | 21 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5,124 | 5,145 | 4,672 | 4,380 | 4,287 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 8 | 65 | 0 | 0 | 0 |
Other Current Liabilities | 340 | 347 | 279 | 269 | 248 |
Total Current Liabilities | 361 | 424 | 291 | 282 | 258 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 70 | 70 | 70 | 69 | 68 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 4 | 4 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 534 | 602 | 471 | 462 | 402 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10 | 10 | 10 | 10 | 9 |
Capital Surplus | 1,809 | 1,818 | 1,813 | 1,778 | 1,743 |
Retained Earnings | 2,762 | 2,694 | 2,362 | 2,113 | 2,119 |
Other Equity | 9 | 21 | 16 | 17 | 14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4,590 | 4,542 | 4,201 | 3,918 | 3,886 |
Total Liabilities & Shareholder's Equity | 5,124 | 5,145 | 4,672 | 4,380 | 4,287 |
Total Common Equity | 4,590 | 4,542 | 4,201 | 3,918 | 3,886 |
Shares Outstanding | 660.70 | 660.60 | 660.30 | 659.60 | 659.60 |
Book Value Per Share | 6.95 | 6.88 | 6.36 | 5.94 | 5.89 |